John Vandermosten
@vanjohn10.bsky.social
Life Sciences, Analyst, Media Operations, Investor Awareness
Owner of Unboxing Biotech, a channel that features life sciences executives and their companies.
Owner of Unboxing Biotech, a channel that features life sciences executives and their companies.
TuHURA Biosciences reports 3Q
*IFx2.0 trial underway
*Delta Opioid Receptor tech @ ASH
*$HURA PR lays out future IFx, VISTA & ADC milestones
finance.yahoo.com/news/tuhura-...
*IFx2.0 trial underway
*Delta Opioid Receptor tech @ ASH
*$HURA PR lays out future IFx, VISTA & ADC milestones
finance.yahoo.com/news/tuhura-...
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for ...
finance.yahoo.com
November 14, 2025 at 2:58 PM
TuHURA Biosciences reports 3Q
*IFx2.0 trial underway
*Delta Opioid Receptor tech @ ASH
*$HURA PR lays out future IFx, VISTA & ADC milestones
finance.yahoo.com/news/tuhura-...
*IFx2.0 trial underway
*Delta Opioid Receptor tech @ ASH
*$HURA PR lays out future IFx, VISTA & ADC milestones
finance.yahoo.com/news/tuhura-...
Reviva Pharmaceuticals reports 3Q
*PreNDA meeting planned in 4Q
*Potential NDA submission 2Q26
*Brilaroxazine EU patent in pulmonary fibrosis
*OLE complete
$RVPH
finance.yahoo.com/news/reviva-...
*PreNDA meeting planned in 4Q
*Potential NDA submission 2Q26
*Brilaroxazine EU patent in pulmonary fibrosis
*OLE complete
$RVPH
finance.yahoo.com/news/reviva-...
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European ...
finance.yahoo.com
November 14, 2025 at 2:42 PM
Reviva Pharmaceuticals reports 3Q
*PreNDA meeting planned in 4Q
*Potential NDA submission 2Q26
*Brilaroxazine EU patent in pulmonary fibrosis
*OLE complete
$RVPH
finance.yahoo.com/news/reviva-...
*PreNDA meeting planned in 4Q
*Potential NDA submission 2Q26
*Brilaroxazine EU patent in pulmonary fibrosis
*OLE complete
$RVPH
finance.yahoo.com/news/reviva-...
We introduce Dr Ann Childress, President of the Center for Psychiatry & Behavioral Medicine & the principal investigator on the CTx-1301 trials. She shares the types of patients that visit her #ADHD practice & how symptoms for younger and older patients differ.
$CING
youtu.be/b3Lmzy-yd0g
$CING
youtu.be/b3Lmzy-yd0g
What Is The Fastest Growing ADHD Population?
YouTube video by Unboxing Biotech
youtu.be
November 14, 2025 at 1:11 PM
We introduce Dr Ann Childress, President of the Center for Psychiatry & Behavioral Medicine & the principal investigator on the CTx-1301 trials. She shares the types of patients that visit her #ADHD practice & how symptoms for younger and older patients differ.
$CING
youtu.be/b3Lmzy-yd0g
$CING
youtu.be/b3Lmzy-yd0g
GeoVax reports 3Q
*Call @ 4:30 pm ET
*Gedeptin expanding to new tumors
*Positive data from COVID vaccine in immunocompromised patients
$GOVX
finance.yahoo.com/news/geovax-...
*Call @ 4:30 pm ET
*Gedeptin expanding to new tumors
*Positive data from COVID vaccine in immunocompromised patients
$GOVX
finance.yahoo.com/news/geovax-...
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
Quarter Highlighted by GEO-MVA Acceleration Amid Global Mpox Emergency, Gedeptin(R) Expansion Into New Solid Tumor Programs, and Strong GEO-CM04S1 Clinical Data in Immunocompromised Patients Company t...
finance.yahoo.com
November 13, 2025 at 9:20 PM
GeoVax reports 3Q
*Call @ 4:30 pm ET
*Gedeptin expanding to new tumors
*Positive data from COVID vaccine in immunocompromised patients
$GOVX
finance.yahoo.com/news/geovax-...
*Call @ 4:30 pm ET
*Gedeptin expanding to new tumors
*Positive data from COVID vaccine in immunocompromised patients
$GOVX
finance.yahoo.com/news/geovax-...
Cingulate reports 3Q & highlights:
*New CCO Downey appointed
*$6mm financing completed
*CTx1301 PDFUA assigned: 31May26
*October AACAP presentation
*Supply agreement with Bend Bio signed
$CING
finance.yahoo.com/news/cingula...
*New CCO Downey appointed
*$6mm financing completed
*CTx1301 PDFUA assigned: 31May26
*October AACAP presentation
*Supply agreement with Bend Bio signed
$CING
finance.yahoo.com/news/cingula...
Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate I...
finance.yahoo.com
November 13, 2025 at 1:33 PM
Cingulate reports 3Q & highlights:
*New CCO Downey appointed
*$6mm financing completed
*CTx1301 PDFUA assigned: 31May26
*October AACAP presentation
*Supply agreement with Bend Bio signed
$CING
finance.yahoo.com/news/cingula...
*New CCO Downey appointed
*$6mm financing completed
*CTx1301 PDFUA assigned: 31May26
*October AACAP presentation
*Supply agreement with Bend Bio signed
$CING
finance.yahoo.com/news/cingula...
Protalix reports 3Q
*call @ 8 am ET
*Revs $17.9mm down 1% y/y
*EPS 3c
$PLX
ir.protalix.com/news-release...
*call @ 8 am ET
*Revs $17.9mm down 1% y/y
*EPS 3c
$PLX
ir.protalix.com/news-release...
Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Protalix BioTherapeutics
ir.protalix.com
November 13, 2025 at 12:34 PM
Protalix reports 3Q
*call @ 8 am ET
*Revs $17.9mm down 1% y/y
*EPS 3c
$PLX
ir.protalix.com/news-release...
*call @ 8 am ET
*Revs $17.9mm down 1% y/y
*EPS 3c
$PLX
ir.protalix.com/news-release...
Azitra reports 3Q
Since last update:
*1st ATR04 patient dosed
*ATR01 data @ BIO Europe
*$2.8mm capital raise
*ATR12 trial continues
$AZTR
finance.yahoo.com/news/azitra-...
Since last update:
*1st ATR04 patient dosed
*ATR01 data @ BIO Europe
*$2.8mm capital raise
*ATR12 trial continues
$AZTR
finance.yahoo.com/news/azitra-...
Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates
Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the...
finance.yahoo.com
November 13, 2025 at 11:46 AM
Azitra reports 3Q
Since last update:
*1st ATR04 patient dosed
*ATR01 data @ BIO Europe
*$2.8mm capital raise
*ATR12 trial continues
$AZTR
finance.yahoo.com/news/azitra-...
Since last update:
*1st ATR04 patient dosed
*ATR01 data @ BIO Europe
*$2.8mm capital raise
*ATR12 trial continues
$AZTR
finance.yahoo.com/news/azitra-...
Dyadic Applied Biosolutions reports 3Q
*call @ 5 pm ET
*1st purchase order for cell culture media
*Proliant & Inzymes milestones paid
$DYAI
dyadic.com/dyadic-annou...
*call @ 5 pm ET
*1st purchase order for cell culture media
*Proliant & Inzymes milestones paid
$DYAI
dyadic.com/dyadic-annou...
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress - Dyadic
JUPITER, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), d/b/a, Dyadic
dyadic.com
November 12, 2025 at 9:17 PM
Dyadic Applied Biosolutions reports 3Q
*call @ 5 pm ET
*1st purchase order for cell culture media
*Proliant & Inzymes milestones paid
$DYAI
dyadic.com/dyadic-annou...
*call @ 5 pm ET
*1st purchase order for cell culture media
*Proliant & Inzymes milestones paid
$DYAI
dyadic.com/dyadic-annou...
Lexaria's Material Transfer Agreement (MTA) with an unidentified pharma company has been extended to 30Apr26
*Original agreement dates to 4Sep24
*Allows extra time to review dataset
*Extends relationship & active license period
$LEXX
finance.yahoo.com/news/materia...
*Original agreement dates to 4Sep24
*Allows extra time to review dataset
*Extends relationship & active license period
$LEXX
finance.yahoo.com/news/materia...
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
KELOWNA, BC / ACCESS Newswire / November 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this upda...
finance.yahoo.com
November 12, 2025 at 2:35 PM
Lexaria's Material Transfer Agreement (MTA) with an unidentified pharma company has been extended to 30Apr26
*Original agreement dates to 4Sep24
*Allows extra time to review dataset
*Extends relationship & active license period
$LEXX
finance.yahoo.com/news/materia...
*Original agreement dates to 4Sep24
*Allows extra time to review dataset
*Extends relationship & active license period
$LEXX
finance.yahoo.com/news/materia...
Radiopharm Theranostics starts 3rd cohort enrollment for RAD204
*Ph1 trial
*PD-L1+ advanced cancers: NSCLC, SCLC, TNBC, HNSCC & others
*90mCi of Lu-177
$RADX
finance.yahoo.com/news/radioph...
*Ph1 trial
*PD-L1+ advanced cancers: NSCLC, SCLC, TNBC, HNSCC & others
*90mCi of Lu-177
$RADX
finance.yahoo.com/news/radioph...
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
Data Safety Monitoring Committee approves advancing to a higher dose of 90mCi The first two Cohorts’ patients show tumor uptake and a favourable safety profile SYDNEY, Nov. 12, 2025 (GLOBE NEWSWIRE) -...
finance.yahoo.com
November 12, 2025 at 2:32 PM
Radiopharm Theranostics starts 3rd cohort enrollment for RAD204
*Ph1 trial
*PD-L1+ advanced cancers: NSCLC, SCLC, TNBC, HNSCC & others
*90mCi of Lu-177
$RADX
finance.yahoo.com/news/radioph...
*Ph1 trial
*PD-L1+ advanced cancers: NSCLC, SCLC, TNBC, HNSCC & others
*90mCi of Lu-177
$RADX
finance.yahoo.com/news/radioph...
Reviva Pharmaceuticals to present anti-inflammatory impacts of brilaroxazine @ Neuroscience 2025
*15-19 November
*San Diego
$RVPH
finance.yahoo.com/news/reviva-...
*15-19 November
*San Diego
$RVPH
finance.yahoo.com/news/reviva-...
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that see...
finance.yahoo.com
November 12, 2025 at 2:29 PM
Reviva Pharmaceuticals to present anti-inflammatory impacts of brilaroxazine @ Neuroscience 2025
*15-19 November
*San Diego
$RVPH
finance.yahoo.com/news/reviva-...
*15-19 November
*San Diego
$RVPH
finance.yahoo.com/news/reviva-...
Spectral AI reports 3Q
*$3.8mm R&D revenue
*Cash $10.5mm as of 30Sep
*$7.6mm capital raise post Q end
*Rev guidance down by $3mm to $18.5mm due to timing
$MDAI
investors.spectral-ai.com/news-release...
*$3.8mm R&D revenue
*Cash $10.5mm as of 30Sep
*$7.6mm capital raise post Q end
*Rev guidance down by $3mm to $18.5mm due to timing
$MDAI
investors.spectral-ai.com/news-release...
investors.spectral-ai.com
November 11, 2025 at 9:06 PM
Spectral AI reports 3Q
*$3.8mm R&D revenue
*Cash $10.5mm as of 30Sep
*$7.6mm capital raise post Q end
*Rev guidance down by $3mm to $18.5mm due to timing
$MDAI
investors.spectral-ai.com/news-release...
*$3.8mm R&D revenue
*Cash $10.5mm as of 30Sep
*$7.6mm capital raise post Q end
*Rev guidance down by $3mm to $18.5mm due to timing
$MDAI
investors.spectral-ai.com/news-release...
Reviva Pharmaceuticals CEO Dr. Laxminarayan Bhat, Ph.D. discusses brilaroxazine's favorable cardiac side effect profile.
youtu.be/EVDygD75wLs
#schizophrenia #biopharma #biotech $RVPH
youtu.be/EVDygD75wLs
#schizophrenia #biopharma #biotech $RVPH
Cardiac Safety Profile
YouTube video by Unboxing Biotech
youtu.be
November 11, 2025 at 2:17 PM
Reviva Pharmaceuticals CEO Dr. Laxminarayan Bhat, Ph.D. discusses brilaroxazine's favorable cardiac side effect profile.
youtu.be/EVDygD75wLs
#schizophrenia #biopharma #biotech $RVPH
youtu.be/EVDygD75wLs
#schizophrenia #biopharma #biotech $RVPH
Cingulate appoints Bryan Downey as Chief Commercial Officer to drive the product launch of CTx-1301.
$CING also completes a $6mm financing.
finance.yahoo.com/news/cingula...
$CING also completes a $6mm financing.
finance.yahoo.com/news/cingula...
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash posit...
finance.yahoo.com
November 10, 2025 at 10:06 PM
Cingulate appoints Bryan Downey as Chief Commercial Officer to drive the product launch of CTx-1301.
$CING also completes a $6mm financing.
finance.yahoo.com/news/cingula...
$CING also completes a $6mm financing.
finance.yahoo.com/news/cingula...
Reviva's brilaroxazine granted EU patent (#3749324) for treatment of pulmonary fibrosis. Builds on similar patents in US, China & Japan.
$RVPH
finance.yahoo.com/news/reviva-...
$RVPH
finance.yahoo.com/news/reviva-...
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
- Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine h...
finance.yahoo.com
November 10, 2025 at 10:02 PM
Reviva's brilaroxazine granted EU patent (#3749324) for treatment of pulmonary fibrosis. Builds on similar patents in US, China & Japan.
$RVPH
finance.yahoo.com/news/reviva-...
$RVPH
finance.yahoo.com/news/reviva-...
Dyadic announces CRISPR/Cas9 licensing agreement with ERS Genomics.
Deal enhances $DYAI's ability to accelerate strain engineering & pathway optimization.
dyadic.com/dyadic-appli...
Deal enhances $DYAI's ability to accelerate strain engineering & pathway optimization.
dyadic.com/dyadic-appli...
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics - Dyadic
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) — ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precisi...
dyadic.com
November 10, 2025 at 9:41 PM
Dyadic announces CRISPR/Cas9 licensing agreement with ERS Genomics.
Deal enhances $DYAI's ability to accelerate strain engineering & pathway optimization.
dyadic.com/dyadic-appli...
Deal enhances $DYAI's ability to accelerate strain engineering & pathway optimization.
dyadic.com/dyadic-appli...
Dyadic to introduce 2 products in Asia: DNase1 & human Transferrin
*Will work with Intralink Group who will conduct business development
*$DYAI will establish supply relationships
www.intralinkgroup.com/latest/news/...
*Will work with Intralink Group who will conduct business development
*$DYAI will establish supply relationships
www.intralinkgroup.com/latest/news/...
Growth in Japan and Korea for US biotech innovator
Intralink is helping Dyadic Applied BioSolutions to expand into Japan and South Korea, targeting biologics and CGT markets with innovative recombinant proteins.
www.intralinkgroup.com
November 10, 2025 at 9:35 PM
Dyadic to introduce 2 products in Asia: DNase1 & human Transferrin
*Will work with Intralink Group who will conduct business development
*$DYAI will establish supply relationships
www.intralinkgroup.com/latest/news/...
*Will work with Intralink Group who will conduct business development
*$DYAI will establish supply relationships
www.intralinkgroup.com/latest/news/...
Azitra addresses false report circulating that it had priced a $44mm offering.
$AZTR asserts that this is untrue.
The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni.
ir.azitrainc.com/news-release...
$AZTR asserts that this is untrue.
The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni.
ir.azitrainc.com/news-release...
Azitra, Inc. Addresses False Report Regarding Sale of Securities | Azitra, Inc.
BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra , Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
ir.azitrainc.com
November 7, 2025 at 1:18 PM
Azitra addresses false report circulating that it had priced a $44mm offering.
$AZTR asserts that this is untrue.
The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni.
ir.azitrainc.com/news-release...
$AZTR asserts that this is untrue.
The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni.
ir.azitrainc.com/news-release...
Rani Therapeutics reports 3Q
*PR reiterates recent capital raise & Chugai deal
*Plan start of RT114 trial before year end
*2 new board members
$RANI
finance.yahoo.com/news/rani-th...
*PR reiterates recent capital raise & Chugai deal
*Plan start of RT114 trial before year end
*2 new board members
$RANI
finance.yahoo.com/news/rani-th...
Rani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What’s Changed
Rani Therapeutics Holdings recently announced a collaboration and license agreement with Chugai Pharmaceutical for the joint development and commercialization of an oral product combining Rani’s RaniP...
finance.yahoo.com
November 6, 2025 at 10:05 PM
Rani Therapeutics reports 3Q
*PR reiterates recent capital raise & Chugai deal
*Plan start of RT114 trial before year end
*2 new board members
$RANI
finance.yahoo.com/news/rani-th...
*PR reiterates recent capital raise & Chugai deal
*Plan start of RT114 trial before year end
*2 new board members
$RANI
finance.yahoo.com/news/rani-th...
It is difficult to have a conversation these days without bringing up Artificial Intelligence. Chief Commercial Officer Jaime Xinos shares how Achieve Life Sciences will use AI to improve their commercialization activities.
$ACHV
youtu.be/WzMWRekgCH8
$ACHV
youtu.be/WzMWRekgCH8
Artificial Intelligence
YouTube video by Unboxing Biotech
youtu.be
November 6, 2025 at 5:31 PM
It is difficult to have a conversation these days without bringing up Artificial Intelligence. Chief Commercial Officer Jaime Xinos shares how Achieve Life Sciences will use AI to improve their commercialization activities.
$ACHV
youtu.be/WzMWRekgCH8
$ACHV
youtu.be/WzMWRekgCH8
Achieve Life Sciences reports 3Q.
Reiterates
*20Jun26 PDUFA
*New legal officer
*Thorax publication
*Vaping priority voucher
*All safety data submitted
*Call @ 8:30 am ET
$ACHV
achievelifesciences.com/achieve-anno...
Reiterates
*20Jun26 PDUFA
*New legal officer
*Thorax publication
*Vaping priority voucher
*All safety data submitted
*Call @ 8:30 am ET
$ACHV
achievelifesciences.com/achieve-anno...
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program - Achieve Life Sciences
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 S...
achievelifesciences.com
November 6, 2025 at 12:25 PM
Achieve Life Sciences reports 3Q.
Reiterates
*20Jun26 PDUFA
*New legal officer
*Thorax publication
*Vaping priority voucher
*All safety data submitted
*Call @ 8:30 am ET
$ACHV
achievelifesciences.com/achieve-anno...
Reiterates
*20Jun26 PDUFA
*New legal officer
*Thorax publication
*Vaping priority voucher
*All safety data submitted
*Call @ 8:30 am ET
$ACHV
achievelifesciences.com/achieve-anno...
Ligand Pharmaceuticals reports 3Q
*Revs of $115mm vs $59mm, beat due to $PTHS
*Core adj EPS of $3.09 vs $1.91
*EPS & Rev guidance up
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...
*Revs of $115mm vs $59mm, beat due to $PTHS
*Core adj EPS of $3.09 vs $1.91
*EPS & Rev guidance up
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and...
investor.ligand.com
November 6, 2025 at 12:20 PM
Ligand Pharmaceuticals reports 3Q
*Revs of $115mm vs $59mm, beat due to $PTHS
*Core adj EPS of $3.09 vs $1.91
*EPS & Rev guidance up
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...
*Revs of $115mm vs $59mm, beat due to $PTHS
*Core adj EPS of $3.09 vs $1.91
*EPS & Rev guidance up
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...
Lantheus reports 3Q
*Revs of $384mm vs our $361mm
*adj EPS of $1.27 vs our $1.16
*CEO to retire
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...
*Revs of $384mm vs our $361mm
*adj EPS of $1.27 vs our $1.16
*CEO to retire
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...
lantheusholdings.gcs-web.com
November 6, 2025 at 12:11 PM
Lantheus reports 3Q
*Revs of $384mm vs our $361mm
*adj EPS of $1.27 vs our $1.16
*CEO to retire
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...
*Revs of $384mm vs our $361mm
*adj EPS of $1.27 vs our $1.16
*CEO to retire
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...
Why is drug half life important & how does this impact the # of CTx-1301 doses needed? The principal investigator for Cingulate Inc.'s trials, Dr. Ann Childress, explains how #ADHD medicines' half life can let symptoms return in the evening.
$CING
youtu.be/pp-zEKCkjGM
$CING
youtu.be/pp-zEKCkjGM
Importance of Drug Half Life
YouTube video by Unboxing Biotech
youtu.be
November 5, 2025 at 7:30 PM
Why is drug half life important & how does this impact the # of CTx-1301 doses needed? The principal investigator for Cingulate Inc.'s trials, Dr. Ann Childress, explains how #ADHD medicines' half life can let symptoms return in the evening.
$CING
youtu.be/pp-zEKCkjGM
$CING
youtu.be/pp-zEKCkjGM
GeoVax to report 3Q on 13Nov.
*Call @ 4:30 pm ET
*Details provided in PR
$GOVX
finance.yahoo.com/news/geovax-...
*Call @ 4:30 pm ET
*Details provided in PR
$GOVX
finance.yahoo.com/news/geovax-...
GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
ATLANTA, GA - November 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases a...
finance.yahoo.com
November 5, 2025 at 1:44 PM
GeoVax to report 3Q on 13Nov.
*Call @ 4:30 pm ET
*Details provided in PR
$GOVX
finance.yahoo.com/news/geovax-...
*Call @ 4:30 pm ET
*Details provided in PR
$GOVX
finance.yahoo.com/news/geovax-...